Botulinum toxin-A therapy for palmar and plantar hyperhidrosis.
In an open study regarding focal hyperhidrosis, we injected 45-65 mouse units of botulinum toxin A (Btx-A) per palm and 100 per sole intracutaneously to 28 hands and 6 feet. We observed patients for up to 10 months to evaluate the efficacy and tolerability of Btx-A for palmar and plantar hyperhidrosis. The mean sweat production significantly declined for both palmar and plantar hyperhidrosis quantitatively on the first month of therapy (P < 0.01). One patient had transient muscle weakness and mild thenar atrophy interfering with her daily activities for 10 days. Injections were otherwise tolerated well by the patients. In this trial Btx-A injection is found to be an effective and safe method of treatment for palmar and plantar hyperhidrosis.
Sevim
Serhan
S
Department of Neurology, Mersin University, Faculty of Medicine, Mersin, Turkey. serhansevim@mail.koc.net
Dogu
Okan
O
Kaleagasi
Hakan
H
D000293:Adolescent; D000328:Adult; D000779:Anesthetics, Local / Q000627:therapeutic use; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage* / Q000009:adverse effects*; D005260:Female; D005528:Foot / Q000503:physiopathology; D006225:Hand / Q000503:physiopathology; D006801:Humans; D006945:Hyperhidrosis / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D007279:Injections, Subcutaneous; D008012:Lidocaine / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D018908:Muscle Weakness / Q000139:chemically induced; D009133:Muscular Atrophy / Q000139:chemically induced; D010146:Pain / Q000188:drug therapy; D012867:Skin / Q000187:drug effects* / Q000503:physiopathology; D013545:Sweat Glands / Q000187:drug effects* / Q000503:physiopathology; D016896:Treatment Outcome
D000779:Anesthetics, Local; D008012:Lidocaine; D019274:Botulinum Toxins, Type A